Physician profile
Sanjay Sethi
NPI 1326081274
$2,125.34
in general payments reported to CMS, 2019-2025
20 companies · $995 in 2025
The $995 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $358 · 2020: $62.53 · 2021: $11.92 · 2022: $280 · 2023: $117 · 2024: $301 · 2025: $995.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,388 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,388.01 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $308.68 | 2021-2025 | Trodelvy |
| Janssen Biotech, INC. | $261.82 | 2022-2025 | Darzalex, Talvey, Erleada |
| E.R. Squibb & Sons, L.L.C. | $198.32 | 2022-2025 | Opdivo |
| Novartis Pharmaceuticals Corporation | $194.14 | 2023-2025 | |
| Astellas Pharma US INC | $144.03 | 2019-2025 | Padcev, Xtandi |
| Karyopharm Therapeutics INC. | $139.26 | 2022 | |
| Merck Sharp & Dohme LLC | $134.18 | 2019-2025 | Lynparza, Keytruda |
| Celgene Corporation | $106.31 | 2023-2025 | Pomalyst, Reblozyl, Opdualag |
| Astrazeneca Pharmaceuticals Lp | $102.80 | 2020-2025 | Tagrisso, Lynparza |
| Circassia INC. | $102.71 | 2019 | |
| Pfizer INC. | $99.41 | 2019-2025 | |
| Beone Medicines USA, INC. | $55.03 | 2025 | Brukinsa |
| Daiichi Sankyo INC. | $53.18 | 2024-2025 | Enhertu, Datroway |
| Stemline Therapeutics INC. | $49.50 | 2025 | Orserdu |
| Tempus Ai, INC | $43.52 | 2024 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beigene USA, INC. | $42.20 | 2024 | Brukinsa |
| Taiho Oncology, INC. | $36.89 | 2024-2025 | |
| Pharmaessentia USA Corporation | $21.34 | 2025 | Besremi |
| Abbvie INC. | $18.32 | 2025 | |
| Amneal Pharmaceuticals LLC | $13.70 | 2025 | Alymsys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sanjay Sethi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.